

SIMPLIFYING COMPLEX GENERICS to build healthier world...

ABOUT US

Committed to develop a healthier world...

Omgene is a diligently, focused and target oriented organization aspiring to mark its presence in the Bio-pharmaceutical space. Our core value is to build a healthier world through developing cutting-edge technologies. Our customer oriented approach inspires us to perform better and keeps us motivated. We deliver as promised to our customers as well as team members.



Established in 2011, as a private limited company

registered under Companies Act. Omgene is a young company working towards making an impact in the global Bio-Pharmaceuticals markets. We believe in Quality, Safety & Efficacy of our products through proactive approach while designing our processes. We offer our products at affordable and realistic prices both in domestic as well as global markets.



Omgene has 20,000 sq ft built up state of the art R&D facility comprising of chemical synthesis, formulation & analytical development laboratories.







QUALITY

A combination of our better technical competency and our experienced team of experts yield high quality products and **Omgene Life Sciences Pvt. Ltd.** is committed to deliver Quality products to Customers, meeting (or) exceeding the expectations consistently in terms of Specification, Delivery, Technical Support, Regulatory Compliance and Competitiveness.





SYNTHETIC RESEARCH

Omgene is presently engaged in more than 30 API development projects. We offer more than 20 generic drug substances for a variety of health issues including oncology, anti-diabetic and anti-fungals. We have the ability to manufacture peptide APIs from gram to kilogram scale and small molecules from gram scale to tons.



ANALYTICAL RESEARCH

The analytical development group works coherently with the organic synthesis and formulation development groups. Technology transfer teams are well placed with sophisticated instruments (NMR, LC-MS/MS, GC, etc.)to provide all essential and stage wise support to our clients on their API development needs.



FORMULATION RESEARCH

Omgene offers formulation development services across diverse dosage forms such as lyophilized parenteral and depot- based systems for domestic as well as global market using QbD approach.

PEPTIDES

Omgene offers highly pure (>99.9%) peptides for domestic market and planning to go for regulatory filing. Expertise in synthesizing long peptides (up-to 40 amino acids).

MAN

KEY STRENGTHS

The company has consistently demonstrated an unfettered imagination and dynamism in meeting all the challenges for complex molecules and our proud strengths are:

- Identification of advanced complex generics for development
- Team of experienced scientists involved in development
- Peptides, Semi-synthetic and advanced small molecules
- · Inhouse capability from mili-gram to Kilo-Gram Scale
- CMOs available for Commercial Quantities
- · Own GMP facility coming soon



CAPABILITIES


- Complex API development
- Formulation development of various dosage forms by QbD approach
- Greater analysis, analytical development and validation support
- Technology transfer and trouble shooting
- DMF, CEP, ANDA filing
- Large / Peptide molecules development and technology transfer

KEY BUSINESS DRIVERS

- Peptides
- Semi-Synthetics
- Steroids
- Fermentation
- Sugar derivatives
- Complex small molecules
- Microspheres

PATENTS

- Synthetic process of Romidepsin. (WO2016084100)
- Methods of making Carfilzomib. (US 9822145 B2)
- Process to prepare Anidulafungin. (WO2016056022)
- Process to prepare Micafungin Sodium. (WO2016056023)
- Preparation of Sugammadex Sodium. (US10494450 B2)
- Preparation of Vortioxetine. (IN20182100185)
- Method of making Micronized Mebendazole by chemical method (20264/MUM/2017)
- Preparation of Lifitegrast. (IN20182100185)
- Process to prepare Midostaurin. (IN201821017401)
- Process to prepare Deutetrabenazine (IN201821003879)
- Process to prepare Degarelix Acetate (IN2019050319)
- Method for preparing GLP-1 analogue by solid-phase peptide synthesis (IN201921036266)
- Improved precess for manufacturing Remdesivir (IN202021051952)






List of Projects

API	STATUS	MARKET
Anidulafungin	Commercial	Eurpoe / Domestic
Apremilast	PDR	US / Europe
Bedaquiline Fumarate	PDR	Domestic
Carbetocin	Commercial	Domestic
Cetrorelix Acetate	Commercial	Domestic
Degarelix Acetate	Commercial	US / Europe / Domestic
Deutetrabenazine	Commercial	US / Europe / Domestic
Everolimus	PDR	Domestic
Ganirelix Acetate	Commercial	Domestic
Ixazomib Citrate	PDR	Domestic
Lanreotide Acetate	Commercial	US / Domestic
Leuprolide Acetate	Commercial	Domestic
Linaclotide	PDR	Domestic
Mebendazole (Micronized)	Commercial	US
Micafungin Sodium	Commercial	Domestic
Midodrine Hydrochloride	PDR	Domestic
Midostaurin	PDR	Domestic
Nitisinone	PDR	Domestic
Obeticholic acid	PDR	Domestic
Octreotide Acetate	Commercial	Domestic
Remdesivir	Commercial	Domestic
Rufinamide	Commercial	Domestic
Sugammadex Sodium	Commercial	US / EU / Domestic
Triptorelin Acetate	PDR	Domestic

List of Projects

API	STATUS
Abaloparatide	PDR
Baricitinib	Development
Binimetinib	Development
Brexanolone	Tech-pack
Brivaracetam	Tech-pack
Crisaborole	Tech-pack
Erdafitinib	Tech-pack
Etelcalcetide	Development
Fulvestrant	Tech-pack
Goserelin Acetate	Tech-pack
Lifitegrast	Tech-pack
Liraglutide	Tech-pack
Nintedanib Esylate	Tech-pack
Oxytocin Acetate	Development
Pentetreotide	Tech-pack
Plecanatide	Development
Ribociclib Succinate	Tech-pack
Sarecycline Hydrochloride	Development
Sincalide	Tech-pack
Semaglutide	Tech-pack
Vismodegib	Tech-pack
Vasopressin	Tech-pack
Terlipressin	Tech-pack





Follow us: Visit our:

INDIA: 333-334, GIDC, Makarpura, Vadodara - 390 010, Gujarat, India.

Phone: +91 265 265 5212

CHINA: Room 435, 4th floor, Building 9, No. 2568 Gudai Road, Minhang District, Shanghai - 201100.

Phone: +86 186 168 068 16

E-mail: info@omgene.com **Web:** www.omgene.com